GlassScriptPhysician profile
Brent Michaels
NPI 1871749648
$5,344.79
in general payments reported to CMS, 2019-2025
28 companies · $307 in 2025
The $307 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $987 · 2020: $418 · 2021: $603 · 2022: $1,012 · 2023: $1,079 · 2024: $939 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,995 · Education: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,994.78 |
| Education | $330.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,487.04 | 2019-2025 | |
| Janssen Biotech, INC. | $579.86 | 2021-2025 | Tremfya, Simponi, Stelara |
| Pfizer INC. | $488.66 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $476.40 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $358.77 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $280.94 | 2021-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $246.14 | 2020-2025 | Absorica Ld, Winlevi, Ilumya |
| Ucb, INC. | $189.41 | 2021-2024 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $163.82 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $160.58 | 2019-2024 | Dupixent, Libtayo |
| Amgen INC. | $155.38 | 2019-2021 | |
| Genzyme Corporation | $110.54 | 2019-2024 | |
| Galderma Laboratories, L.P. | $71.49 | 2019-2025 | Nemluvio |
| Incyte Corporation | $69.15 | 2022-2023 | Opzelura |
| Almirall LLC | $66.00 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $55.17 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Celgene Corporation | $55.15 | 2019 | |
| Lilly USA, LLC | $53.68 | 2022-2024 | Taltz, Zepbound, Olumiant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.44 | 2023 | Spevigo |
| Merz North America, INC. | $46.73 | 2021 | |
| Arcutis Biotherapeutics, INC. | $39.25 | 2023-2024 | Zoryve |
| Vyne Pharmaceuticals INC. | $26.20 | 2020 | |
| Genentech USA, INC. | $25.53 | 2019 | |
| Merck Sharp & Dohme LLC | $25.40 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.11 | 2024 | Cabtreo |
| Helsinn Therapeutics (U.S.), INC. | $17.87 | 2023 | Valchlor |
| Strata Skin Sciences, INC. | $13.15 | 2024 | Xtrac |
| Mylan Pharmaceuticals INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Michaels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.